Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study

Abstract Background Although angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) have been shown to preserve residual kidney function in a select group of Asian patients undergoing continuous ambulatory peritoneal dialysis (PD) in two small randomized clinical...

Full description

Bibliographic Details
Main Authors: Jenny I. Shen, Anjali B. Saxena, Sitaram Vangala, Satvinder K. Dhaliwal, Wolfgang C. Winkelmayer
Format: Article
Language:English
Published: BMC 2017-06-01
Series:BMC Nephrology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12882-017-0616-4
_version_ 1818847815984480256
author Jenny I. Shen
Anjali B. Saxena
Sitaram Vangala
Satvinder K. Dhaliwal
Wolfgang C. Winkelmayer
author_facet Jenny I. Shen
Anjali B. Saxena
Sitaram Vangala
Satvinder K. Dhaliwal
Wolfgang C. Winkelmayer
author_sort Jenny I. Shen
collection DOAJ
description Abstract Background Although angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) have been shown to preserve residual kidney function in a select group of Asian patients undergoing continuous ambulatory peritoneal dialysis (PD) in two small randomized clinical trials, the effectiveness of these drugs has yet to be demonstrated in a more diverse population of patients with multiple comorbid conditions. We investigated the association between ACEI/ARB use and development of recorded anuria in a cohort of patients initiating PD in the U.S. Methods We conducted a retrospective observational cohort study using the US Renal Data System and electronic health records data from a large national dialysis provider. We identified adult patients who initiated PD from 2007 to 2011. Only patients who participated in the federal prescription drug benefit program, Medicare Part D, for the first 90 days of dialysis were included. Patients who filled a prescription for an ACEI or ARB during those 90 days were considered users. We applied Cox proportional hazards models to an inverse probability of treatment-weighted (IPTW) cohort to estimate the hazard ratio (HR) for anuria (24-h urine volume < 200 ml) in ACEI/ARB users vs. non-users. Results Among 886 patients, 389 (44%) used an ACEI/ARB. Almost a third of these patients were black or Hispanic, and more than a quarter had comorbidities that would have excluded them from the randomized clinical trials of ACEI/ARB. Two hundred eighty patients reached anuria over 840 person-years of follow-up, for a composite event rate of 33 events per 100 person-years. We found no clear association between ACEI/ARB use and progression to anuria [HR: 0.86, 95% CI: 0.73–1.02]. Conclusions ACEI/ARB use is common in patients initiating PD in the U.S. but was not associated with a lower risk of anuria. Residual confounding by unmeasured variables is an important limitation of this observational study. Still, these findings suggest that pragmatic clinical trials are warranted to test the effectiveness of ACEI/ARB in slowing the decline of residual kidney function in a diverse population of peritoneal dialysis patients with multiple comorbid conditions.
first_indexed 2024-12-19T06:07:27Z
format Article
id doaj.art-3c0b200b887647c2ba6331ab2dfb8976
institution Directory Open Access Journal
issn 1471-2369
language English
last_indexed 2024-12-19T06:07:27Z
publishDate 2017-06-01
publisher BMC
record_format Article
series BMC Nephrology
spelling doaj.art-3c0b200b887647c2ba6331ab2dfb89762022-12-21T20:33:06ZengBMCBMC Nephrology1471-23692017-06-0118111010.1186/s12882-017-0616-4Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort studyJenny I. Shen0Anjali B. Saxena1Sitaram Vangala2Satvinder K. Dhaliwal3Wolfgang C. Winkelmayer4Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterDivision of Nephrology, Department of Medicine, Stanford University School of MedicineDepartment of Medicine Statistics Core, David Geffen School of Medicine at UCLADepartment of Medicine Statistics Core, David Geffen School of Medicine at UCLADivision of Nephrology, Department of Medicine, Stanford University School of MedicineAbstract Background Although angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) have been shown to preserve residual kidney function in a select group of Asian patients undergoing continuous ambulatory peritoneal dialysis (PD) in two small randomized clinical trials, the effectiveness of these drugs has yet to be demonstrated in a more diverse population of patients with multiple comorbid conditions. We investigated the association between ACEI/ARB use and development of recorded anuria in a cohort of patients initiating PD in the U.S. Methods We conducted a retrospective observational cohort study using the US Renal Data System and electronic health records data from a large national dialysis provider. We identified adult patients who initiated PD from 2007 to 2011. Only patients who participated in the federal prescription drug benefit program, Medicare Part D, for the first 90 days of dialysis were included. Patients who filled a prescription for an ACEI or ARB during those 90 days were considered users. We applied Cox proportional hazards models to an inverse probability of treatment-weighted (IPTW) cohort to estimate the hazard ratio (HR) for anuria (24-h urine volume < 200 ml) in ACEI/ARB users vs. non-users. Results Among 886 patients, 389 (44%) used an ACEI/ARB. Almost a third of these patients were black or Hispanic, and more than a quarter had comorbidities that would have excluded them from the randomized clinical trials of ACEI/ARB. Two hundred eighty patients reached anuria over 840 person-years of follow-up, for a composite event rate of 33 events per 100 person-years. We found no clear association between ACEI/ARB use and progression to anuria [HR: 0.86, 95% CI: 0.73–1.02]. Conclusions ACEI/ARB use is common in patients initiating PD in the U.S. but was not associated with a lower risk of anuria. Residual confounding by unmeasured variables is an important limitation of this observational study. Still, these findings suggest that pragmatic clinical trials are warranted to test the effectiveness of ACEI/ARB in slowing the decline of residual kidney function in a diverse population of peritoneal dialysis patients with multiple comorbid conditions.http://link.springer.com/article/10.1186/s12882-017-0616-4Peritoneal dialysisRenin angiotensin system blockersAngiotensin converting enzyme inhibitorsAngiotensin receptor blockersResidual kidney function
spellingShingle Jenny I. Shen
Anjali B. Saxena
Sitaram Vangala
Satvinder K. Dhaliwal
Wolfgang C. Winkelmayer
Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study
BMC Nephrology
Peritoneal dialysis
Renin angiotensin system blockers
Angiotensin converting enzyme inhibitors
Angiotensin receptor blockers
Residual kidney function
title Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study
title_full Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study
title_fullStr Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study
title_full_unstemmed Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study
title_short Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study
title_sort renin angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis an observational cohort study
topic Peritoneal dialysis
Renin angiotensin system blockers
Angiotensin converting enzyme inhibitors
Angiotensin receptor blockers
Residual kidney function
url http://link.springer.com/article/10.1186/s12882-017-0616-4
work_keys_str_mv AT jennyishen reninangiotensinsystemblockersandresidualkidneyfunctionlossinpatientsinitiatingperitonealdialysisanobservationalcohortstudy
AT anjalibsaxena reninangiotensinsystemblockersandresidualkidneyfunctionlossinpatientsinitiatingperitonealdialysisanobservationalcohortstudy
AT sitaramvangala reninangiotensinsystemblockersandresidualkidneyfunctionlossinpatientsinitiatingperitonealdialysisanobservationalcohortstudy
AT satvinderkdhaliwal reninangiotensinsystemblockersandresidualkidneyfunctionlossinpatientsinitiatingperitonealdialysisanobservationalcohortstudy
AT wolfgangcwinkelmayer reninangiotensinsystemblockersandresidualkidneyfunctionlossinpatientsinitiatingperitonealdialysisanobservationalcohortstudy